
Imagine a world where aspiring surgeons can hone their skills without the constant presence of an expert mentor, receiving precise, real-time feedback as they practice critical techniques like suturing. This scenario is no longer a distant dream but a reality being shaped by an innovative AI-driven
I'm thrilled to be speaking with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development has positioned him at the forefront of cutting-edge cancer treatment technologies. Today, we’ll dive into the groundbreaking work on nanodots made from molybdenum
Families and clinicians have long wrestled with the same question: when choices span medication, therapy, and a dozen hopeful alternatives, which option is most likely to help right now without creating new problems later, and how confident should anyone be in that promise. That recurring
Jan Kaiserle sits down with Ivan Kairatov, a biopharma expert deeply versed in molecular therapeutics and translational research, to discuss a new approach to overcoming treatment resistance in neuroblastoma. Drawing on work published in Science Advances in 2025, Kairatov explains how a failed
Ivan Kairatov is a biopharma expert with a track record bridging preclinical discovery and translational development across oncology subtypes. He has worked at the interface of receptor biology, pharmacology, and clinical trial design, and he brings a pragmatic lens to drug repurposing. In this
Imagine a silent epidemic affecting thousands of men each year, often undetected until it’s too late, with societal norms discouraging open conversations about personal health challenges, and prostate cancer standing as the most common cancer among men in the UK, with around 55,000 new cases
Imagine a scenario where a patient, battling cancer that has spread to the brain, undergoes complex treatments like radiation or chemotherapy, only to face uncertainty when follow-up scans can’t clearly show whether the tumor is growing or if the changes are just treatment side effects. This
Diving into the world of virology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development. With a deep understanding of technology and innovation in the industry, Ivan has been at the forefront of groundbreaking discoveries.
In the rapidly advancing world of biotechnology and medicine, protein engineering stands as a cornerstone for innovation, yet it faces persistent challenges in designing proteins with precise, tailored functionalities that meet specific needs. For years, scientists have wrestled with the
The alarming statistic that individuals with type 1 diabetes face a 4.29-fold increased risk of developing bladder cancer has sent ripples through the medical community, challenging long-held assumptions about the intersection of metabolic disorders and malignancies. With bladder cancer already
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy